baricitinib vs upadacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK · full Atopic Dermatitis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Phase 3 in Atopic Dermatitissmall molecule
Reliable signal

NCT03334396 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.

Next expected readout: May 2030 · NCT07262983 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)

Result source: NCT03334422

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Atopic DermatitisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT03607422 · Phase 3 · completed

Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)

Result source: NCT03607422

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibupadacitinib
EASI-7531.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
IGA 0/1 with 2-point improvement13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
—Trial running · NCT03568318
EASI-9016% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
EASI, % change-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117

EASI-75

baricitinib
31.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
upadacitinib
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117

IGA 0/1 with 2-point improvement

baricitinib
13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
upadacitinib
—Trial running · NCT03568318

EASI-90

baricitinib
16% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
upadacitinib
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117

EASI, % change

baricitinib
-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
upadacitinib
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. baricitinib: 10 of 10 rows · upadacitinib: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Rows use multiple source trials
upadacitinib
Rows use multiple source trials
BSA
absolute change · percentage points
-25.66% (n=115) vs -20.31% (n=105) placebo @ 16wkHigh Dosea,b,c,d
NCT03952559 · Phase 3 · registry result, not featured evidence
show 2 more doses
-21.83% (n=109) vs -20.31% (n=105) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-22.06% (n=113) vs -20.31% (n=105) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-27.1% (n=42) vs -4.1% (n=39) placebo @ 16wk15 mga,b,c,d
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
-30.7% (n=42) vs -4.1% (n=39) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-11.7% (n=42) vs -4.1% (n=39) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
EASI-50
responder rate · % of participants
41.6% (n=125) vs 15.3% (n=249) placebo @ 16wk4 mga,b,c,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
30.1% (n=123) vs 15.3% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
26% (n=127) vs 15.3% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71.4% (n=42) vs 22% (n=41) placebo @ 16wk15 mga,b,c,d
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
83.3% (n=42) vs 22% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 22% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
EASI-75
responder rate · % of participants
No placebo or comparator arm
45.4% (n=194) @ 24wk4 mga,e,c,d
NCT03334435 · Phase 3 · registry result, not featured evidence
show 3 more doses
32.1% (n=28) @ 24wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
45% (n=180) @ 24wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
32.4% (n=34) @ 24wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
97.2% (n=71) @ 24wk15 mga,e,c,d
NCT05507580 · Phase 4 · registry result, not featured evidence
show 3 more doses
69.2% (n=133) @ 24wk15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
88.5% (n=130) @ 24wk30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
52.4% (n=82) @ 24wk30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
IGA 0/1
responder rate · % of participants
13.8% (n=123) vs 4.5% (n=244) placebo @ 16wk4 mga,b,c,d
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
10.6% (n=123) vs 4.5% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.8% (n=125) vs 4.5% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
31% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mga,b,c,d
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
SCORAD75
responder rate · % of participants
10.4% (n=125) vs 1.2% (n=249) placebo @ 16wk4 mga,b,c,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
7.3% (n=123) vs 1.2% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
5.5% (n=127) vs 1.2% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21.4% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mga,b,c,d
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
40.5% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
SCORAD90
responder rate · % of participants
2.4% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mga,b,c,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.5% (n=42) vs 0% (n=41) placebo @ 16wk15 mga,b,c,d
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
23.8% (n=42) vs 0% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4% (n=42) vs 0% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Dropout rate
4%4 mgf
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.7%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.9%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
98%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
97.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
7.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
6.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
14%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
13%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
8.3%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
32.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
—15 mgg
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
5.2%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
4.1%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
3.2%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
4.5%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
3.3%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
4.9%30 mg QD
NCT03569293 · Phase 3
5.2%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
2.6%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
10.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
16.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
8.8%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.9%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%4 mgf
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.6%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
2.7%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
0.9%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
8.1%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
—15 mgg
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0.4%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
0.4%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
1.6%30 mg QD
NCT03569293 · Phase 3
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
2%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Serious AEs
1.6%4 mgf
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
0%4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.3%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
1.7%Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0.8%Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
9.5%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
13.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
5.4%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
6.4%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.3%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
4.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
9.4%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
2.2%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
28.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.9%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
11.1%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
19.2%2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
9.1%Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
12.5%2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.5%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.9%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
15.4%1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
21.4%1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0.7%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.8%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.6%4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
5.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
15.4%15 mgg
NCT03607422 · Phase 3
show 48 more results
10.9%15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
10.6%15 mg
NCT03607422 · Phase 3
16.6%15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
13.8%30 mg
NCT03607422 · Phase 3
16.9%30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
17.3%30 mg
NCT03607422 · Phase 3
17.4%30 mg
NCT03607422 · Phase 3
2.8%30 mg QD
NCT03607422 · Phase 3
3.3%15 mg
NCT03569293 · Phase 3
12.5%15 mg QD
NCT03569293 · Phase 3
3.1%15 mg QD
NCT03569293 · Phase 3
14.7%15 mg
NCT03569293 · Phase 3
14.3%15 mg
NCT03569293 · Phase 3
2.1%15 mg QD
NCT03569293 · Phase 3
22.2%30 mg
NCT03569293 · Phase 3
10.9%30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
20%30 mg
NCT03569293 · Phase 3
18.4%30 mg
NCT03569293 · Phase 3
3.3%30 mg QD
NCT03569293 · Phase 3
3.5%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.4%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.7%15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.8%30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
5.9%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
5.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.1%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
6.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
4 mgf
nasopharyngitis 9.6% (placebo 10.4%)
headache 8% (placebo 6.4%)
cough 3.2% (placebo 0.8%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 47 more results
4 mg
abdominal pain 12.5% (placebo 0.4%)
nausea 12.5% (placebo 0.8%)
oedema peripheral 12.5% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
headache 11.4% (placebo 6.4%)
nasopharyngitis 9.8% (placebo 10.4%)
abdominal pain 2.4% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
pyrexia 12.5% (placebo 0%)
urinary tract infection 12.5% (placebo 1.6%)
abdominal pain 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 17.3% (placebo 10.4%)
diarrhoea 7.1% (placebo 2.8%)
headache 5.5% (placebo 6.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
pyrexia 20% (placebo 0%)
abdominal pain 0% (placebo 0.4%)
anaemia 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4 mg
headache 8.9% (placebo 2%)
nasopharyngitis 8.1% (placebo 12.3%)
blood creatine phosphokinase increased 5.7% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
nasopharyngitis 13% (placebo 12.3%)
headache 7.3% (placebo 2%)
herpes simplex 5.7% (placebo 0.8%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 10.5% (placebo 12.3%)
headache 4.8% (placebo 2%)
blood creatine phosphokinase increased 3.2% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
High Dose
abdominal pain 5% (placebo 2.5%)
acne 5% (placebo 4.1%)
headache 5% (placebo 8.2%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Low Dose
headache 5.8% (placebo 8.2%)
bronchitis 5% (placebo 0.8%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Mid Dose
headache 9.2% (placebo 8.2%)
abdominal pain 4.2% (placebo 2.5%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
High Dose
nasopharyngitis 6.1% (placebo 4.9%)
abdominal pain upper 3% (placebo 0.8%)
chapped lips 3% (placebo 0%)
NCT03952559 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 11% (placebo 2.2%)
herpes zoster 9.8% (placebo 0%)
nasopharyngitis 9.8% (placebo 5.4%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 2.2%)
nasopharyngitis 13.1% (placebo 5.4%)
blood creatine phosphokinase increased 6% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 16.4% (placebo 5.4%)
upper respiratory tract infection 5.9% (placebo 4.3%)
oral herpes 5.4% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 13.3% (placebo 2.2%)
nasopharyngitis 10.8% (placebo 5.4%)
headache 5.6% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 15.2% (placebo 2.2%)
nasopharyngitis 10.9% (placebo 5.4%)
headache 5.4% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.5% (placebo 5.4%)
urinary tract infection 7.1% (placebo 1.1%)
covid-19 4.8% (placebo 2.2%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 13.8% (placebo 5.4%)
headache 6% (placebo 3.3%)
upper respiratory tract infection 5.6% (placebo 4.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 21.9% (placebo 2.2%)
alanine aminotransferase increased 9.4% (placebo 0%)
dermal cyst 6.3% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 9.9% (placebo 2.2%)
vulvovaginal candidiasis 6.7% (placebo 0%)
folliculitis 5.5% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 20% (placebo 5.4%)
pyrexia 4.4% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 37% (placebo 10.3%)
influenza 15.2% (placebo 3.4%)
headache 10.9% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 13.8%)
dysmenorrhoea 14.3% (placebo 0%)
upper respiratory tract infection 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 57.1% (placebo 10.3%)
covid-19 28.6% (placebo 13.8%)
gastroenteritis 28.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 4 mg
nasopharyngitis 50% (placebo 10.3%)
abdominal pain upper 16.7% (placebo 0%)
migraine 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 2 mg
nasopharyngitis 18.8% (placebo 10.3%)
upper respiratory tract infection 18.8% (placebo 3.4%)
arthralgia 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 4 mg
covid-19 25% (placebo 13.8%)
bronchitis 18.8% (placebo 0%)
herpes simplex 18.8% (placebo 6.9%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 19.6% (placebo 10.3%)
influenza 8.2% (placebo 3.4%)
headache 7.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 22.7% (placebo 10.3%)
covid-19 18.2% (placebo 13.8%)
herpes zoster 13.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
covid-19 14.8% (placebo 13.8%)
vulvovaginal candidiasis 14.3% (placebo 0%)
nasopharyngitis 11.1% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 4 mg
covid-19 19.2% (placebo 13.8%)
herpes zoster 15.4% (placebo 0%)
skin infection 15.4% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 2 mg
acne 9.1% (placebo 0%)
anaemia 9.1% (placebo 0%)
covid-19 9.1% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
headache 20% (placebo 3.4%)
vulvovaginal candidiasis 20% (placebo 0%)
covid-19 16% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 1 mg
nasopharyngitis 33.3% (placebo 10.3%)
covid-19 12.5% (placebo 13.8%)
pain in extremity 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 17.2% (placebo 10.3%)
folliculitis 9.7% (placebo 0%)
headache 8.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
dysmenorrhoea 23.1% (placebo 0%)
covid-19 17.6% (placebo 13.8%)
nasopharyngitis 11.8% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 2 mg
herpes simplex 15.4% (placebo 6.9%)
herpes zoster 15.4% (placebo 0%)
nasopharyngitis 15.4% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 4 mg
conjunctivitis 21.4% (placebo 0%)
covid-19 21.4% (placebo 13.8%)
uterine polypectomy 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 6.9% (placebo 6.2%)
nasopharyngitis 6.2% (placebo 7.5%)
diarrhoea 4.1% (placebo 1.4%)
NCT03435081 · Phase 3 · registry result, not featured evidence
2 mg
prostate cancer 9.1% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 6.2%)
urinary tract infection 8.6% (placebo 2.1%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 6.1% (placebo 6.2%)
back pain 2% (placebo 0.7%)
blood creatine phosphokinase increased 2% (placebo 0.7%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 10.5% (placebo 6.2%)
ovarian cyst ruptured 6.7% (placebo 0%)
actinic keratosis 5.3% (placebo 0%)
NCT03435081 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 15.3% (placebo 12%)
folliculitis 5.4% (placebo 0%)
upper respiratory tract infection 2.7% (placebo 1.9%)
NCT03733301 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 11% (placebo 12%)
upper respiratory tract infection 7.3% (placebo 1.9%)
folliculitis 3.7% (placebo 0%)
NCT03733301 · Phase 3 · registry result, not featured evidence
4 mg
blood creatine phosphokinase increased 13.2% (placebo 2%)
headache 13.2% (placebo 0%)
nasopharyngitis 10.5% (placebo 4.1%)
NCT02576938 · Phase 2 · registry result, not featured evidence
2 mg
dermatitis atopic 8.1% (placebo 10.2%)
gastrooesophageal reflux disease 5.4% (placebo 0%)
headache 5.4% (placebo 0%)
NCT02576938 · Phase 2 · registry result, not featured evidence
15 mgg
covid-19 23.1% (placebo 0%)
acne 19.2% (placebo 3.3%)
dermatitis atopic 19.2% (placebo 13.3%)
NCT03607422 · Phase 3
show 38 more results
15 mg
covid-19 27.3% (placebo 0%)
upper respiratory tract infection 21.8% (placebo 1.7%)
acne 18.2% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg QD
acne 10.3% (placebo 3.3%)
upper respiratory tract infection 10.3% (placebo 1.7%)
oropharyngeal pain 6.9% (placebo 0%)
NCT03607422 · Phase 3
15 mg
covid-19 31.7% (placebo 0%)
acne 19.2% (placebo 3.3%)
blood creatine phosphokinase increased 17.3% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg
covid-19 31.9% (placebo 0%)
dermatitis atopic 17.9% (placebo 13.3%)
upper respiratory tract infection 14.4% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg QD
acne 12.8% (placebo 3.3%)
headache 7% (placebo 3.3%)
nasopharyngitis 6.2% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 41.4% (placebo 0%)
acne 34.5% (placebo 3.3%)
dermatitis atopic 24.1% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 32.2% (placebo 0%)
blood creatine phosphokinase increased 18.6% (placebo 1.7%)
acne 11.9% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg QD
acne 14.5% (placebo 3.3%)
blood creatine phosphokinase increased 9.7% (placebo 1.7%)
headache 8.1% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 39.4% (placebo 0%)
acne 25% (placebo 3.3%)
dermatitis atopic 15.4% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 29.8% (placebo 0%)
blood creatine phosphokinase increased 18.3% (placebo 1.7%)
dermatitis atopic 14.9% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg QD
acne 15% (placebo 3.3%)
nasopharyngitis 8.1% (placebo 3.3%)
headache 6.5% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg
covid-19 20% (placebo 0%)
acne 16.7% (placebo 1.6%)
blood creatine phosphokinase increased 16.7% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
covid-19 25% (placebo 0%)
upper respiratory tract infection 21.9% (placebo 8.2%)
blood creatine phosphokinase increased 12.5% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
acne 14.1% (placebo 1.6%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
headache 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg
covid-19 38.2% (placebo 0%)
dermatitis atopic 18.6% (placebo 3.3%)
upper respiratory tract infection 18.6% (placebo 8.2%)
NCT03569293 · Phase 3
15 mg
covid-19 28.6% (placebo 0%)
nasopharyngitis 16.5% (placebo 1.6%)
dermatitis atopic 16% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
upper respiratory tract infection 9.6% (placebo 8.2%)
nasopharyngitis 7.9% (placebo 1.6%)
acne 5.4% (placebo 1.6%)
NCT03569293 · Phase 3
30 mg
acne 37% (placebo 1.6%)
upper respiratory tract infection 33.3% (placebo 8.2%)
dermatitis atopic 29.6% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
covid-19 35.9% (placebo 0%)
acne 28.1% (placebo 1.6%)
upper respiratory tract infection 28.1% (placebo 8.2%)
NCT03569293 · Phase 3
30 mg QD
acne 15.6% (placebo 1.6%)
upper respiratory tract infection 12.5% (placebo 8.2%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 38.1% (placebo 0%)
acne 22.9% (placebo 1.6%)
blood creatine phosphokinase increased 17.1% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 35.1% (placebo 0%)
acne 18.9% (placebo 1.6%)
dermatitis atopic 18% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
acne 16.5% (placebo 1.6%)
upper respiratory tract infection 12.8% (placebo 8.2%)
nasopharyngitis 11.5% (placebo 1.6%)
NCT03569293 · Phase 3
15 mg
acne 7%
nasopharyngitis 5.7%
upper respiratory tract infection 3.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg
nasopharyngitis 11.1%
dermatitis atopic 8.3%
upper respiratory tract infection 6.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg then 30 mg
dermatitis atopic 16%
nasopharyngitis 4.2%
acne 2.8%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 13.8%
nasopharyngitis 9.1%
dermatitis atopic 3.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg then 15 mg
dermatitis atopic 12%
nasopharyngitis 7.5%
acne 6%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
dermatitis atopic 16.5%
acne 6.6%
eczema 5.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 20.5%
covid-19 13.4%
blood creatine phosphokinase increased 13%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg
acne 22.9%
dermatitis atopic 19.1%
blood creatine phosphokinase increased 14.8%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg QD
acne 18.7%
dermatitis atopic 10.5%
blood creatine phosphokinase increased 7.6%
NCT03738397 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
nasopharyngitis 11.9% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 11.9% (placebo 5.4%)
nasopharyngitis 9.5% (placebo 1.1%)
blood creatine phosphokinase increased 7.1% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 22.8% (placebo 5.4%)
dermatitis atopic 19.3% (placebo 2.2%)
acne 11.4% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
acne 14.3% (placebo 1.1%)
upper respiratory tract infection 11.9% (placebo 5.4%)
blood creatine phosphokinase increased 9.5% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 14.3% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fPopulation comparability has not been reviewed for 42 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

IGA 0 1 Improvement 16.8% (n=125) vs 4.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
10.4% (n=125) vs 2.4% (n=249) placebo @ 4wk4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.4% (n=123) vs 4.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9% (n=123) vs 2.4% (n=249) placebo @ 4wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.8% (n=127) vs 4.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.1% (n=127) vs 2.4% (n=249) placebo @ 4wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Itch NRS 4-Point Improvement 21.5% (n=107) vs 7.2% (n=222) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
18.7% (n=107) vs 4.7% (n=213) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
41% (n=61) vs 32.6% (n=43) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
46.4% (n=56) vs 37.5% (n=32) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
38.2% (n=76) vs 8.2% (n=85) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
44% (n=100) vs 20.2% (n=104) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
12% (n=100) vs 7.2% (n=222) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.1% (n=106) vs 4.7% (n=213) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
32.6% (n=43) vs 32.6% (n=43) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
45.8% (n=48) vs 37.5% (n=32) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
22.9% (n=166) vs 8.2% (n=85) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
25.2% (n=131) vs 5.7% (n=123) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
38.1% (n=97) vs 20.2% (n=104) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
10.5% (n=105) vs 7.2% (n=222) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6% (n=100) vs 4.7% (n=213) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25.8% (n=31) vs 32.6% (n=43) placebo @ 16wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
23.1% (n=78) vs 8.2% (n=85) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
15.9% (n=132) vs 5.7% (n=123) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
ADSS Item 2 -1.42 vs -0.84 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
-1.38 vs -0.8 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.42 vs -0.63 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.42 vs -0.51 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.04 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.21 vs -0.8 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.85 vs -0.63 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.4 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-1.33 vs -0.51 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.21 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.1 vs -0.8 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.05 vs -0.63 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.62 vs -0.4 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-0.35 vs -0.42 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.43 vs -0.42 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.55 vs -0.42 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
Skin Pain NRS -1.93 vs -0.84 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
-2.49 vs -0.86 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.02 vs -1.56 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-3.73 vs -2.06 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.58 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.61 vs -0.86 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -1.56 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.4 vs -1.03 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-3.22 vs -2.06 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.92 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.09 vs -0.86 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.27 vs -1.56 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.16 vs -1.03 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-1.23 vs -1.15 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-1.56 vs -1.15 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-1.77 vs -1.15 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
IGA 0 1.6% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.3% (n=92) vs 0% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
8.1% (n=111) vs 2.8% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.1% (n=185) vs 0% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.7% (n=146) vs 0.7% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.7% (n=109) vs 2.8% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.6% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4% (n=125) vs 1.6% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=93) vs 0% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=147) vs 0.7% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
5% (n=121) vs 4.1% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
5% (n=120) vs 4.1% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
12.5% (n=120) vs 4.1% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
SCORAD -28.3 vs -13.51 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-27.5 vs -13.35 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.74 vs -21.98 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-35.78 vs -21.4 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-26.54 vs -11.89 placebo score @ 16wk4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-21.47 vs -13.51 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27.83 vs -13.35 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.54 vs -21.98 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-26.18 vs -14.37 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-29.88 vs -21.4 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-23.87 vs -11.89 placebo score @ 16wk2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-18.85 vs -13.51 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-20.23 vs -13.35 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.06 vs -21.98 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-18.31 vs -14.37 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-24.82 vs -20.93 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-26.08 vs -20.93 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-28.55 vs -20.93 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
BSA -25.96 vs -14.8 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 10 more results
-23.98 vs 12.82 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.17 vs -19.76 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-29.73 vs -18.03 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-20.14 vs -14.8 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-22.12 vs 12.82 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.26 vs -19.76 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-27 vs -18.03 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-20.79 vs -14.8 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-18.98 vs 12.82 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.98 vs -19.76 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
Itch NRS -36.55% (n=68) vs -12.04% (n=68) placebo @ 16wk4 mg
percent change · % of baseline
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
46.87% (n=47) vs -16.58% (n=48) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-37.24% (n=66) vs -17.48% (n=53) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-29.31% (n=56) vs -12.13% (n=44) placebo @ 52wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-51.22% (n=94) vs -27% (n=89) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-29.43% (n=50) vs -12.04% (n=68) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
47.24% (n=38) vs -16.58% (n=48) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-32.89% (n=135) vs -17.48% (n=53) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-16.01% (n=110) vs -12.13% (n=44) placebo @ 52wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-39.87% (n=73) vs -18.01% (n=36) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-43.44% (n=98) vs -27% (n=89) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-31.3% (n=52) vs -12.04% (n=68) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.39% (n=31) vs -16.58% (n=48) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.8% (n=62) vs -17.48% (n=53) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-19.49% (n=54) vs -12.13% (n=44) placebo @ 52wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-30.28% (n=64) vs -18.01% (n=36) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
POEM Total -7.84 vs -2.68 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 6 more results
-10.83 vs -5.6 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-6.26 vs -2.68 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.44 vs -2.67 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-8.5 vs -5.6 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-5.32 vs -2.68 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.57 vs -2.67 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
PGI-S-AD -0.77 vs -0.31 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 10 more results
-0.96 vs -0.27 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.18 vs -0.69 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-0.58 vs -0.31 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.88 vs -0.27 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.06 vs -0.69 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-0.58 vs -0.31 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.53 vs -0.27 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.56 vs -0.33 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.64 vs -0.33 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.83 vs -0.33 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
HADS Anxiety -2.05 vs -0.9 placebo score @ 16wk4 mg
absolute change · score
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
-2.3 vs -0.99 placebo score @ 16wk4 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.32 vs -0.48 placebo score @ 16wk4 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.89 placebo score @ 16wk4 mg
Anxiety
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.83 vs -0.9 placebo score @ 16wk2 mg
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.92 vs -0.99 placebo score @ 16wk2 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.59 vs -0.48 placebo score @ 16wk2 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.55 vs -2.03 placebo score @ 16wk2 mg
Anxiety
NCT03435081 · Phase 3 · registry result, not featured evidence
-2.7 vs -1.89 placebo score @ 16wk2 mg
Anxiety
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.35 vs -0.9 placebo score @ 16wk1 mg
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.93 vs -0.99 placebo score @ 16wk1 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.04 vs -0.48 placebo score @ 16wk1 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.5 vs -2.03 placebo score @ 16wk1 mg
Anxiety
NCT03435081 · Phase 3 · registry result, not featured evidence
HADS Depression -1.5 vs -0.37 placebo score @ 16wk4 mg
absolute change · score
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
-1.46 vs -0.28 placebo score @ 16wk4 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.57 vs -0.4 placebo score @ 16wk4 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.33 vs -1.31 placebo score @ 16wk4 mg
Depression
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.37 placebo score @ 16wk2 mg
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.99 vs -0.28 placebo score @ 16wk2 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.03 vs -0.4 placebo score @ 16wk2 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.73 vs -1.31 placebo score @ 16wk2 mg
Depression
NCT03435081 · Phase 3 · registry result, not featured evidence
-2.05 vs -1.31 placebo score @ 16wk2 mg
Depression
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.04 vs -0.37 placebo score @ 16wk1 mg
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.78 vs -0.28 placebo score @ 16wk1 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.69 vs -0.4 placebo score @ 16wk1 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.87 vs -1.31 placebo score @ 16wk1 mg
Depression
NCT03435081 · Phase 3 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

upadacitinib

vIGA-AD 0 1 38.8% (n=276) vs 4.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
44.8% (n=58) vs 5% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
48.1% (n=281) vs 8.4% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
46% (n=63) vs 6.9% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
52% (n=282) vs 4.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
59.4% (n=62) vs 5% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=285) vs 8.4% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=58) vs 6.9% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
Worst Itch NRS 4-Point Improvement 41.9% (n=270) vs 9.1% (n=274) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 38 more results
48.9% (n=270) vs 3.6% (n=274) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=270) vs 0.7% (n=274) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=269) vs 0.7% (n=267) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
11.5% (n=269) vs 3% (n=267) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
12.7% (n=55) vs 0% (n=59) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
8.9% (n=56) vs 0% (n=59) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
14.3% (n=56) vs 1.7% (n=59) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
52.2% (n=274) vs 11.8% (n=272) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
51.5% (n=274) vs 4.4% (n=272) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
15% (n=274) vs 0.4% (n=272) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
10.5% (n=275) vs 3.7% (n=270) placebo @ 0.29wk15 mg QD
NCT03569293 · Phase 3
16.4% (n=275) vs 3.3% (n=270) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 10.5% (n=57) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 3.5% (n=57) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
9.8% (n=61) vs 0% (n=57) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
16.9% (n=59) vs 5.4% (n=56) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
59.6% (n=280) vs 9.1% (n=274) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
60.7% (n=280) vs 3.6% (n=274) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
15.7% (n=280) vs 0.7% (n=274) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
7.9% (n=278) vs 0.7% (n=267) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
17.3% (n=278) vs 3% (n=267) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
56.7% (n=60) vs 3.4% (n=59) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
50% (n=60) vs 3.4% (n=59) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
5% (n=60) vs 0% (n=59) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
3.2% (n=62) vs 0% (n=59) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
9.7% (n=62) vs 1.7% (n=59) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
60% (n=280) vs 11.8% (n=272) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
66.8% (n=280) vs 4.4% (n=272) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
19.6% (n=280) vs 0.4% (n=272) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
11.8% (n=279) vs 3.7% (n=270) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
21.1% (n=279) vs 3.3% (n=270) placebo @ 0.43wk30 mg QD
NCT03569293 · Phase 3
58.9% (n=56) vs 10.5% (n=57) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
64.3% (n=56) vs 3.5% (n=57) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
23.2% (n=56) vs 0% (n=57) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
14% (n=57) vs 1.8% (n=56) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
56.1% (n=334) vs 36.4% (n=323) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
Disease Flare 2.2% (n=274) vs 24.5% (n=269) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
1.7% (n=58) vs 20% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
1.1% (n=279) vs 25.2% (n=274) placebo15 mg QD
NCT03569293 · Phase 3
0% (n=62) vs 23.2% (n=56) placebo15 mg QD
NCT03569293 · Phase 3
1.4% (n=277) vs 24.5% (n=269) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
1.6% (n=61) vs 20% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
0% (n=285) vs 25.2% (n=274) placebo30 mg QD
NCT03569293 · Phase 3
0% (n=58) vs 23.2% (n=56) placebo30 mg QD
NCT03569293 · Phase 3
EASI 100 14.1% (n=276) vs 0.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 8 more results
15.5% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
16.7% (n=281) vs 1.8% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
15.9% (n=63) vs 0% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
18.8% (n=282) vs 0.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
19.4% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
27% (n=285) vs 1.8% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
34.5% (n=58) vs 0% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
28.4% (n=342) vs 7.9% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
WI-NRS -51.2% (n=224) vs -17.04% (n=119) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 7 more results
-47.56% (n=49) vs -11.02% (n=27) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-62.79% (n=225) vs -26.06% (n=123) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-59.01% (n=49) vs -24.36% (n=31) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-66.49% (n=235) vs -17.04% (n=119) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-66.95% (n=55) vs -11.02% (n=27) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.04% (n=236) vs -26.06% (n=123) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-70% (n=51) vs -24.36% (n=31) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
POEM 4-Point Improvement 70.9% (n=268) vs 28.7% (n=268) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
66.1% (n=56) vs 28.1% (n=57) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75% (n=278) vs 22.8% (n=276) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
80.6% (n=62) vs 27.3% (n=55) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
83.5% (n=269) vs 28.7% (n=268) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
80.7% (n=57) vs 28.1% (n=57) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
81.4% (n=280) vs 22.8% (n=276) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
87.9% (n=58) vs 27.3% (n=55) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
DLQI 4-point Improvement 71.7% (n=251) vs 28.4% (n=250) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
68.2% (n=22) vs 19.2% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75.4% (n=254) vs 29% (n=250) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
81.5% (n=27) vs 33.3% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
77.6% (n=251) vs 28.4% (n=250) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
73.3% (n=30) vs 19.2% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
82% (n=256) vs 29% (n=250) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
79.3% (n=29) vs 33.3% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
SCORAD -57.9% (n=245) vs -28.43% (n=136) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 13 more results
-57.89% (n=54) vs -27.91% (n=30) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-65.71% (n=239) vs -32.68% (n=125) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-65.42% (n=58) vs -30.9% (n=30) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-44.1% (n=36) vs -7% (n=33) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-46.9% (n=36) vs -12.4% (n=33) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-68.44% (n=241) vs -28.43% (n=136) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.81% (n=49) vs -27.91% (n=30) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-73.07% (n=253) vs -32.68% (n=125) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-76.35% (n=57) vs -30.9% (n=30) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-65.3% (n=40) vs -7% (n=33) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-60.4% (n=40) vs -12.4% (n=33) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-35.4% (n=39) vs -7% (n=33) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-32.5% (n=39) vs -12.4% (n=33) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
DLQI 0/1 23.8% (n=252) vs 4.7% (n=257) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
13.6% (n=22) vs 7.7% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
30.3% (n=258) vs 4.4% (n=252) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
22.2% (n=27) vs 4.8% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
37.9% (n=256) vs 4.7% (n=257) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
46.9% (n=32) vs 7.7% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
41.5% (n=261) vs 4.4% (n=252) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
30% (n=30) vs 4.8% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-IS Sleep Domain 12 Point Improvement 55% (n=218) vs 13.2% (n=220) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
47.9% (n=48) vs 13.3% (n=45) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
66.1% (n=218) vs 13.2% (n=220) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=41) vs 13.3% (n=45) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-SS Skin Pain 4-Point Improvement 53.6% (n=237) vs 15% (n=233) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
43.4% (n=53) vs 9.8% (n=41) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
63.5% (n=249) vs 15% (n=233) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
67.9% (n=53) vs 9.8% (n=41) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-SS TSS-7 28 Point Improvement 53.6% (n=233) vs 15% (n=226) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
51% (n=51) vs 13% (n=46) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
67.9% (n=246) vs 15% (n=226) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70% (n=50) vs 13% (n=46) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3

+ 16 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: JAK · full Rheumatoid Arthritis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Approved in Rheumatoid Arthritissmall molecule
Reliable signal

NCT01710358 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.

Next expected readout: March 2027 · NCT04870203 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)

Result source: NCT02265705

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02675426 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).

Next expected readout: March 2027 · NCT07636057 (registry estimate)

Reported efficacy

Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)

Result source: NCT03086343

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibupadacitinib
ACR2061.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
ACR5044.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
ACR7024.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
DAS28-CRP remission—Trial running · NCT0487020348.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
HAQ-DI, change-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705
Modified Sharp score, change0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873

ACR20

baricitinib
61.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
upadacitinib
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705

ACR50

baricitinib
44.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
upadacitinib
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

ACR70

baricitinib
24.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
upadacitinib
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

DAS28-CRP remission

baricitinib
—Trial running · NCT04870203
upadacitinib
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389

HAQ-DI, change

baricitinib
-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
upadacitinib
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705

Modified Sharp score, change

baricitinib
0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
upadacitinib
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. baricitinib: 11 of 11 rows · upadacitinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Rows use multiple source trials
upadacitinib
Rows use multiple source trials
Boolean Remission
responder rate · % of participants
7.2% (n=487) vs 1% (n=488) placebo @ 12wka,b
NCT01710358 · Phase 3
4 other source trials
13.8% (n=159) vs 5.7% (n=210) Methotrexate @ 12wk
NCT01711359 · Phase 3
14.4% (n=215) vs 5.7% (n=210) Methotrexate @ 12wk
NCT01711359 · Phase 3 · combination
7% (n=229) vs 0.4% (n=228) placebo @ 12wk2 mg
NCT01721057 · Phase 3
6.6% (n=227) vs 0.4% (n=228) placebo @ 12wk4 mg
NCT01721057 · Phase 3
9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mgc,a,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI
absolute change · score
-23 vs -13.53 placebo score @ 12wka,b
NCT01710358 · Phase 3
-17.5 vs -14.57 placebo score @ 12wk60 mgc,a,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-16.7 vs -14.57 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-27 vs -14.57 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.51 vs -14.57 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS28-CRP
absolute change · score
-2.74 vs -2.01 Methotrexate score @ 24wkc,b
NCT01711359 · Phase 3
show 1 more dose
-2.82 vs -2.01 Methotrexate score @ 24wk
NCT01711359 · Phase 3 · combination
-3.07 vs -2.15 Methotrexate score @ 24wk15 mgc,b
NCT02706873 · Phase 3
show 1 more dose
-3.34 vs -2.15 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
DAS28-ESR
absolute change · score
-1.97 vs -1.16 placebo score @ 12wk4 mgc,a,b
NCT01721057 · Phase 3
show 1 more dose
-1.89 vs -1.16 placebo score @ 12wk2 mg
NCT01721057 · Phase 3
-1.41 vs -1.18 placebo score @ 12wk60 mgc,a,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-1.24 vs -1.18 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.53 vs -1.18 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.44 vs -1.18 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
FACIT-Fatigue
absolute change · score
9.6 vs 6.8 placebo score @ 12wkb,d
NCT01710358 · Phase 3
4 other source trials
8.7 vs 7.6 placebo score @ 12wk2 mg
NCT01721057 · Phase 3
8.8 vs 7.6 placebo score @ 12wk4 mg
NCT01721057 · Phase 3
8.8 vs 5.9 placebo score @ 12wk2 mg
NCT01721044 · Phase 3
8.5 vs 5.9 placebo score @ 12wk4 mg
NCT01721044 · Phase 3
7.91 vs 2.96 placebo score @ 12wk15 mgc,b,d
NCT02675426 · Phase 3
show 1 more dose
7.74 vs 2.96 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
Morning Stiffness Duration
absolute change · minutes
-55 vs -40 Methotrexate minutes @ 52wkc,b,e
NCT01711359 · Phase 3
show 1 more dose
-60 vs -40 Methotrexate minutes @ 52wk
NCT01711359 · Phase 3 · combination
-94.56 vs -53.03 Methotrexate minutes @ 14wk15 mgc,b,e
NCT02706951 · Phase 3
show 1 more dose
-102.34 vs -53.03 Methotrexate minutes @ 14wk30 mg
NCT02706951 · Phase 3
SDAI
absolute change · score
-18.17 vs -4.54 placebo score @ 12wk4 mgc,b
NCT01469013 · Phase 2
show 3 more doses
-16.85 vs -4.54 placebo score @ 12wk2 mg
NCT01469013 · Phase 2
-18.02 vs -4.54 placebo score @ 12wk8 mg
NCT01469013 · Phase 2
-13.11 vs -4.54 placebo score @ 12wk1 mg
NCT01469013 · Phase 2
-18.01 vs -14.44 placebo score @ 12wk60 mgc,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-17.12 vs -14.44 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.73 vs -14.44 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Dropout rate
5.9%Baricitinibf
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
15%Baricitinib
NCT01711359 · Phase 3
19.5%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
6.2%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
10.1%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
8.3%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
9.8%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
51.7%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
51.1%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
55.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
60.8%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
33.7%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
94.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
75.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
70.2%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
95.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
100%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
76.9%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
72.8%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—15 mgf
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.6%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
8.2%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
12.6%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
14%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
7.3%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
7.4%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
4.7%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
4.8%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
9.7%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.1%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
7.3%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.5%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
10%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
14%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
6%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
12%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.1%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
16.4%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.7%Baricitinibf
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
6.3%Baricitinib
NCT01711359 · Phase 3
11.2%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
1.4%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
4.4%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
5.6%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
4%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
13.5%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
12.6%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
8.3%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
5.7%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
6%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
12.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
21.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
18.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
11.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
14.5%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
16.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—15 mgf
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
1.4%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
4.1%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
5.7%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
3.5%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
5.5%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
2.3%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
1.4%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
0.6%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
2.4%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
1.6%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
10%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.6%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
10.9%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Serious AEs
—Baricitinibf
NCT01710358 · Phase 3
show 43 more results
0%Baricitinib Follow-up
NCT01710358 · Phase 3
5.3%Baricitinib Treatment A
NCT01710358 · Phase 3
3.8%BaricitinibTreatment B
NCT01710358 · Phase 3
7.5%Baricitinib
NCT01711359 · Phase 3
7.9%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
0%Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
0%Baricitinib - Follow-up
NCT01711359 · Phase 3
2.8%4 mg
NCT02265705 · Phase 3
1.7%4 mg
NCT02265705 · Phase 3
2.5%4 mg
NCT02265705 · Phase 3
9.5%Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
0%4 mg
NCT01469013 · Phase 2
4.2%2 mg
NCT01469013 · Phase 2
4.2%8 mg
NCT01469013 · Phase 2
0%1 mg
NCT01469013 · Phase 2
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
4.5%4 mg
NCT01721057 · Phase 3
2.6%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
0%2 mg
NCT01721057 · Phase 3
—4 mg
NCT01721044 · Phase 3
0%4 mg
NCT01721044 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
11.1%2 mg
NCT01721044 · Phase 3
4.6%2 mg
NCT01721044 · Phase 3
31.3%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
29.5%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
23.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
22.9%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
20%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
30%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
37.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
27.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
28.1%15 mgf
NCT02675426 · Phase 3
show 55 more results
4.5%15 mg
NCT02675426 · Phase 3
10.6%15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.2%30 mg
NCT02675426 · Phase 3
31.8%30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
15.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3
5%15 mg
NCT02706873 · Phase 3 · monotherapy
21.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3
6.4%30 mg
NCT02706873 · Phase 3 · monotherapy
22.6%30 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3
9.1%7.5 mg
NCT02706873 · Phase 3 · monotherapy
23.6%7.5 mg
NCT02706873 · Phase 3 · monotherapy
4%15 mg QD
NCT03086343 · Phase 3
23.6%15 mg QD
NCT03086343 · Phase 3
19%30 mg QD
NCT03086343 · Phase 3
35.3%30 mg QD
NCT03086343 · Phase 3
5.1%15 mg
NCT02706951 · Phase 3
10.7%15 mg
NCT02706951 · Phase 3
29.9%15 mg
NCT02706951 · Phase 3
2.8%30 mg
NCT02706951 · Phase 3
24.1%30 mg
NCT02706951 · Phase 3
—15 mg
NCT02706847 · Phase 3
15.2%15 mg
NCT02706847 · Phase 3
5.5%15 mg
NCT02706847 · Phase 3
36.9%15 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
29.6%30 mg
NCT02706847 · Phase 3
17.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
7.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
21.9%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
27.3%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
13.8%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
22.5%12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
13.8%6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.1%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
6%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
4%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
1.8%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
f
alanine aminotransferase increased 0% (placebo 0%)
anaemia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT01710358 · Phase 3
show 30 more results
nasopharyngitis 7.6% (placebo 6.1%)
urinary tract infection 4.3% (placebo 0%)
bronchitis 3.9% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 5.7% (placebo 6.1%)
upper respiratory tract infection 3.1% (placebo 0%)
bronchitis 2.8% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 10.1%
upper respiratory tract infection 7.5%
gastroenteritis 6.3%
NCT01711359 · Phase 3
nasopharyngitis 9.8%
nausea 9.3%
upper respiratory tract infection 7.4%
NCT01711359 · Phase 3 · combination
abdominal discomfort 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT01711359 · Phase 3 · combination
constipation 6.7%
eczema asteatotic 6.7%
miliaria 6.7%
NCT01711359 · Phase 3
4 mg
upper respiratory tract infection 19.3% (placebo 0%)
hyperlipidaemia 11% (placebo 0%)
urinary tract infection 9% (placebo 0%)
NCT02265705 · Phase 3
4 mg
arthralgia 5.2% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT02265705 · Phase 3
4 mg
upper respiratory tract infection 9.2% (placebo 0%)
hyperlipidaemia 7.5% (placebo 0%)
benign prostatic hyperplasia 7.1% (placebo 0%)
NCT02265705 · Phase 3
blood creatine phosphokinase increased 6.8% (placebo 0%)
upper respiratory tract infection 6.8% (placebo 0%)
nasopharyngitis 5.4% (placebo 0%)
NCT02265705 · Phase 3
4 mg
blood creatine phosphokinase increased 8.3% (placebo 4.1%)
liver function test abnormal 8.3% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
NCT01469013 · Phase 2
2 mg
hepatic function abnormal 12.5% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
cystitis 4.2% (placebo 4.1%)
NCT01469013 · Phase 2
8 mg
blood creatine phosphokinase increased 12.5% (placebo 4.1%)
hepatic function abnormal 12.5% (placebo 0%)
hypercholesterolaemia 12.5% (placebo 0%)
NCT01469013 · Phase 2
1 mg
nasopharyngitis 8.3% (placebo 12.2%)
anaemia 4.2% (placebo 0%)
chronic sinusitis 4.2% (placebo 0%)
NCT01469013 · Phase 2
4 mg
upper respiratory tract infection 10.6% (placebo 0%)
nasopharyngitis 7.9% (placebo 0%)
blood creatine phosphokinase increased 6.6% (placebo 5.9%)
NCT01721057 · Phase 3
4 mg
cough 4.5% (placebo 0%)
dyspnoea 4.5% (placebo 0%)
gastritis 4.5% (placebo 0%)
NCT01721057 · Phase 3
2 mg
headache 6.6% (placebo 0%)
upper respiratory tract infection 6.1% (placebo 0%)
urinary tract infection 5.2% (placebo 0%)
NCT01721057 · Phase 3
2 mg
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
acne 0% (placebo 0%)
NCT01721057 · Phase 3
4 mg
cervicitis 5.6% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT01721044 · Phase 3
4 mg
headache 6.8% (placebo 0%)
bronchitis 5.6% (placebo 0%)
nausea 5.6% (placebo 0%)
NCT01721044 · Phase 3
2 mg
cellulitis 11.1% (placebo 0%)
insomnia 11.1% (placebo 0%)
lymphopenia 11.1% (placebo 0%)
NCT01721044 · Phase 3
2 mg
headache 9.8% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 0%)
nasopharyngitis 6.9% (placebo 5.3%)
NCT01721044 · Phase 3
4 mg
covid-19 23.3%
nasopharyngitis 13.8%
urinary tract infection 11.4%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 20.8%
nasopharyngitis 11.6%
urinary tract infection 11.3%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
4 mg
covid-19 8.4%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 8.8%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
4 mg
bronchitis 11.3%
nasopharyngitis 11.3%
upper respiratory tract infection 10.9%
NCT01885078 · Phase 3 · registry result, not featured evidence
4 mg
bronchitis 10.9%
nasopharyngitis 9.8%
influenza 9.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 19.5%
urinary tract infection 17.8%
bronchitis 16.2%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.1%
upper respiratory tract infection 7.8%
bronchitis 7.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
15 mgf
upper respiratory tract infection 19.8% (placebo 4.1%)
nasopharyngitis 18.5% (placebo 4.1%)
urinary tract infection 17% (placebo 3.6%)
NCT02675426 · Phase 3
show 48 more results
15 mg
nausea 6.8% (placebo 3.2%)
nasopharyngitis 5.4% (placebo 4.1%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 8.9% (placebo 0%)
rheumatoid arthritis 4.5% (placebo 4.5%)
fall 2.8% (placebo 0.5%)
NCT02675426 · Phase 3
30 mg
nasopharyngitis 5.9% (placebo 4.1%)
upper respiratory tract infection 5.5% (placebo 4.1%)
headache 3.7% (placebo 5.4%)
NCT02675426 · Phase 3
30 mg
upper respiratory tract infection 17.8% (placebo 4.1%)
urinary tract infection 14.3% (placebo 3.6%)
nasopharyngitis 14% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 10.5%
rheumatoid arthritis 9.4%
urinary tract infection 7.2%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 6.3%
nasopharyngitis 5.7%
nausea 5.7%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 15.5%
nasopharyngitis 15.1%
urinary tract infection 13.6%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 10.8%
upper respiratory tract infection 7.3%
urinary tract infection 5.7%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 16.2%
nasopharyngitis 16.2%
hypertension 14%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 9.1%
pharyngitis 9.1%
stomatitis 7.3%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 40%
herpes zoster 21.8%
pharyngitis 21.8%
NCT02706873 · Phase 3 · monotherapy
15 mg QD
upper respiratory tract infection 8.6%
nasopharyngitis 7.3%
urinary tract infection 6.6%
NCT03086343 · Phase 3
15 mg QD
covid-19 23.6%
urinary tract infection 14.8%
nasopharyngitis 13.7%
NCT03086343 · Phase 3
30 mg QD
rheumatoid arthritis 14.3%
arthralgia 9.5%
cough 9.5%
NCT03086343 · Phase 3
30 mg QD
hypertension 23.5%
upper respiratory tract infection 23.5%
bronchitis 17.6%
NCT03086343 · Phase 3
15 mg
urinary tract infection 4.6%
upper respiratory tract infection 4.1%
blood creatine phosphokinase increased 2.3%
NCT02706951 · Phase 3
15 mg
covid-19 9.8%
urinary tract infection 6.3%
rheumatoid arthritis 4.4%
NCT02706951 · Phase 3
15 mg
nasopharyngitis 17.6%
rheumatoid arthritis 14.2%
urinary tract infection 13.5%
NCT02706951 · Phase 3
30 mg
urinary tract infection 4.7%
blood creatine phosphokinase increased 4.2%
upper respiratory tract infection 2.8%
NCT02706951 · Phase 3
30 mg
blood creatine phosphokinase increased 18.6%
urinary tract infection 15.1%
upper respiratory tract infection 14.8%
NCT02706951 · Phase 3
15 mg
rheumatoid arthritis 9.4% (placebo 5.9%)
urinary tract infection 8% (placebo 5.9%)
back pain 5.8% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
urinary tract infection 9.8% (placebo 5.9%)
upper respiratory tract infection 7.9% (placebo 7.7%)
bronchitis 4.3% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 31.4% (placebo 7.7%)
urinary tract infection 18.2% (placebo 5.9%)
nasopharyngitis 14.4% (placebo 6.5%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 6.7% (placebo 7.7%)
nasopharyngitis 5.5% (placebo 6.5%)
urinary tract infection 5.5% (placebo 5.9%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 27.9% (placebo 7.7%)
urinary tract infection 20.4% (placebo 5.9%)
nasopharyngitis 17.1% (placebo 6.5%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 20.2% (placebo 6.5%)
alanine aminotransferase increased 9.3% (placebo 1.2%)
blood creatine phosphokinase increased 9% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 9.5% (placebo 6.5%)
alanine aminotransferase increased 5.3% (placebo 1.2%)
anaemia 0% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
nasopharyngitis 54.7% (placebo 10.2%)
herpes zoster 14.1% (placebo 2%)
influenza 14.1% (placebo 4.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
15 mg
nasopharyngitis 12.2% (placebo 10.2%)
liver function test increased 6.1% (placebo 0%)
constipation 4.1% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 43.9% (placebo 10.2%)
constipation 15.2% (placebo 0%)
herpes zoster 15.2% (placebo 2%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 18% (placebo 10.2%)
blood creatine phosphokinase increased 6% (placebo 0%)
headache 6% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 53.8% (placebo 10.2%)
stomatitis 20% (placebo 6.1%)
hypertension 12.3% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 10.2% (placebo 10.2%)
hypertension 6.1% (placebo 0%)
stomatitis 6.1% (placebo 6.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12 mg BID/30 mg QD
upper respiratory tract infection 20.3%
urinary tract infection 15%
herpes zoster 11.2%
NCT02049138 · Phase 2 · registry result, not featured evidence
6 mg BID/15 mg QD
upper respiratory tract infection 9.9%
nasopharyngitis 9.5%
urinary tract infection 9.5%
NCT02049138 · Phase 2 · registry result, not featured evidence
60 mg
urinary tract infection 9.8% (placebo 0%)
diarrhoea 7.3% (placebo 0%)
rheumatoid arthritis 7.3% (placebo 10.5%)
NCT03682705 · Phase 2 · registry result, not featured evidence
20 mg
rheumatoid arthritis 7.7% (placebo 10.5%)
upper respiratory tract infection 7.7% (placebo 5.3%)
alopecia 5.1% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
15 mg/60 mg
upper respiratory tract infection 6.5% (placebo 5.3%)
arthralgia 1.6% (placebo 5.3%)
cough 1.6% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
5 mg
rheumatoid arthritis 7.3% (placebo 10.5%)
upper respiratory tract infection 4.9% (placebo 5.3%)
urinary tract infection 4.9% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
24 mg QD
nasopharyngitis 6.1% (placebo 2%)
back pain 2% (placebo 0%)
blood creatine phosphokinase increased 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
blood creatine phosphokinase increased 4% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
12 mg BID
influenza 8% (placebo 0%)
nasopharyngitis 8% (placebo 2%)
blood creatine phosphokinase increased 6% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
6 mg BID
back pain 6% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
3 mg BID
headache 4% (placebo 2%)
back pain 2% (placebo 0%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
urinary tract infection 12.7% (placebo 3.6%)
blood creatine phosphokinase increased 9.1% (placebo 0%)
constipation 7.3% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
12 mg BID
upper respiratory tract infection 7.3% (placebo 1.8%)
headache 5.5% (placebo 1.8%)
leukopenia 5.5% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
6 mg BID
headache 5.5% (placebo 1.8%)
hyperlipidaemia 3.6% (placebo 1.8%)
constipation 1.8% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
3 mg BID
nausea 7.3% (placebo 1.8%)
arthralgia 5.5% (placebo 0%)
headache 5.5% (placebo 1.8%)
NCT01960855 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 14 weeks versus 52 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

ACR50 45% (n=487) vs 16.8% (n=488) placebo @ 12wk
responder rate · % of participants
ACR50 Week 12
NCT01710358 · Phase 3
ACR50 50.5% (n=487) vs 19.3% (n=488) placebo @ 24wk
responder rate · % of participants
ACR50 Week 24
NCT01710358 · Phase 3
ACR50 55.9% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR50 Week 52
NCT01710358 · Phase 3
ACR70 18.9% (n=487) vs 4.7% (n=488) placebo @ 12wk
responder rate · % of participants
ACR70 Week 12
NCT01710358 · Phase 3
ACR70 29.8% (n=487) vs 8% (n=488) placebo @ 24wk
responder rate · % of participants
ACR70 Week 24
NCT01710358 · Phase 3
ACR70 37.2% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR70 Week 52
NCT01710358 · Phase 3
SDAI Remission 17% (n=24) vs 8% (n=49) placebo @ 12wk4 mg
responder rate · % of participants
NCT01469013 · Phase 2
show 13 more results
8.8% (n=227) vs 0.9% (n=228) placebo @ 12wk4 mg
NCT01721057 · Phase 3
5.1% (n=177) vs 1.7% (n=176) placebo @ 12wk4 mg
NCT01721044 · Phase 3
29% (n=24) vs 8% (n=49) placebo @ 12wk2 mg
NCT01469013 · Phase 2
9.2% (n=229) vs 0.9% (n=228) placebo @ 12wk2 mg
NCT01721057 · Phase 3
2.3% (n=174) vs 1.7% (n=176) placebo @ 12wk2 mg
NCT01721044 · Phase 3
17% (n=24) vs 8% (n=49) placebo @ 12wk8 mg
NCT01469013 · Phase 2
4% (n=24) vs 8% (n=49) placebo @ 12wk1 mg
NCT01469013 · Phase 2
8.4% (n=487) vs 1.8% (n=488) placebo @ 12wk
NCT01710358 · Phase 3
16% (n=487) vs 3.1% (n=488) placebo @ 24wk
NCT01710358 · Phase 3
22.6% (n=487) vs NA placebo @ 52wk
NCT01710358 · Phase 3
22% (n=159) vs 10.5% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3
22.8% (n=215) vs 10.5% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3 · combination
1.4% (n=145) vs 0% (n=145) placebo @ 12wk*
NCT02265705 · Phase 3 · converted to % from 2 Participants as posted
SF-36 Mental Component Summary 3.3 vs 3.2 placebo score @ 12wk
absolute change · score
MCS Week 12
NCT01710358 · Phase 3
SF-36 Mental Component Summary 3.8 vs 2.2 placebo score @ 24wk
absolute change · score
MCS Week 24
NCT01710358 · Phase 3
SF-36 Mental Component Summary 4 vs NA placebo score @ 52wk
absolute change · score
MCS Week 52
NCT01710358 · Phase 3
SF-36 Physical Component Summary 8.9 vs 4.3 placebo score @ 12wk
absolute change · score
PCS Week 12
NCT01710358 · Phase 3
SF-36 Physical Component Summary 9.9 vs 4.6 placebo score @ 24wk
absolute change · score
PCS Week 24
NCT01710358 · Phase 3

+ 73 further endpoints in the CSV export.

upadacitinib

DAS Low Disease Activity 48.4% (n=221) vs 17.2% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 21 more results
53.3% (n=317) vs 28.3% (n=314) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
77.8% (n=27) vs 17.9% (n=28) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
44.7% (n=217) vs 19.4% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
43.3% (n=164) vs 14.2% (n=169) placebo @ 12wk15 mg
NCT02706847 · Phase 3
46.2% (n=169) vs 13.6% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
69.4% (n=49) vs 18.4% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
47.9% (n=219) vs 17.2% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
54.8% (n=314) vs 28.3% (n=314) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
78.6% (n=28) vs 17.9% (n=28) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
53% (n=215) vs 19.4% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
42.4% (n=165) vs 14.2% (n=169) placebo @ 12wk30 mg
NCT02706847 · Phase 3
72% (n=50) vs 18.4% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
69.1% (n=55) vs 17.9% (n=28) Methotrexate @ 12wk7.5 mg
NCT02706873 · Phase 3
53.1% (n=49) vs 18.4% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
42.9% (n=49) vs 21.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
51% (n=49) vs 21.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
46% (n=50) vs 21.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
57.1% (n=49) vs 21.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
49% (n=49) vs 21.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
SF-36 PCS 7.58 vs 3.03 placebo score @ 12wk15 mg
absolute change · score
NCT02675426 · Phase 3
show 16 more results
9.99 vs 5.74 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
10.7 vs 6.97 Methotrexate score @ 24wk15 mg
NCT02706873 · Phase 3
10.79 vs 2.87 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
8.28 vs 4.32 Methotrexate score @ 14wk15 mg
NCT02706951 · Phase 3
5.83 vs 2.39 placebo score @ 12wk15 mg
NCT02706847 · Phase 3
8.93 vs 3.36 placebo score @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
6.38 vs 2.88 placebo score @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
8.01 vs 3.03 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
10.08 vs 5.74 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
11.39 vs 6.97 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
9.63 vs 2.87 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
10.19 vs 4.32 Methotrexate score @ 14wk30 mg
NCT02706951 · Phase 3
7.02 vs 2.39 placebo score @ 12wk30 mg
NCT02706847 · Phase 3
8.81 vs 2.88 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
8.84 vs 2.87 Methotrexate score @ 12wk7.5 mg
NCT02706873 · Phase 3
7.21 vs 2.88 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
DAS28 (CRP) Remission 30.8% (n=221) vs 10% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 22 more results
48.3% (n=317) vs 18.5% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
70.4% (n=27) vs 17.9% (n=28) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
30% (n=303) vs 13.3% (n=309) Abatacept @ 12wk15 mg QD
NCT03086343 · Phase 3
28.1% (n=217) vs 8.3% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
29.6% (n=169) vs 5.3% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
57.1% (n=49) vs 6.1% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
28.3% (n=219) vs 10% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
50% (n=314) vs 18.5% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
82.1% (n=28) vs 17.9% (n=28) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
40.5% (n=215) vs 8.3% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
50% (n=50) vs 6.1% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
67.3% (n=55) vs 17.9% (n=28) Methotrexate @ 24wk7.5 mg
NCT02706873 · Phase 3
36.7% (n=49) vs 6.1% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
19.5% (n=41) vs 10.5% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
22.4% (n=49) vs 14.9% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
7.7% (n=39) vs 10.5% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
42.9% (n=49) vs 14.9% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
32.3% (n=62) vs 10.5% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
34% (n=50) vs 14.9% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
38.8% (n=49) vs 14.9% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.8% (n=41) vs 10.5% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 14.9% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
CDAI Low Disease Activity 40.3% (n=221) vs 19% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 23 more results
35.5% (n=169) vs 11.2% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
42% (n=219) vs 19% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
9.8% (n=41) vs 10.5% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 5.3% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
34.1% (n=41) vs 26.3% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 21.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 10.5% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.7% (n=39) vs 10.5% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
20.5% (n=39) vs 5.3% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.9% (n=39) vs 26.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
49% (n=49) vs 21.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
16.1% (n=62) vs 10.5% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
29% (n=62) vs 10.5% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
46.8% (n=62) vs 5.3% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
37.1% (n=62) vs 26.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
40% (n=50) vs 21.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2.4% (n=41) vs 10.5% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
24.4% (n=41) vs 5.3% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 26.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
mTSS no Progression 87.5% (n=279) vs 77.7% (n=264) Methotrexate @ 24wk15 mg
responder rate · % of participants
NCT02706873 · Phase 3
show 4 more results
80.8% (n=26) vs 46.2% (n=26) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
89.3% (n=270) vs 77.7% (n=264) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
79.2% (n=24) vs 46.2% (n=26) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
82.4% (n=51) vs 46.2% (n=26) Methotrexate @ 24wk7.5 mg
NCT02706873 · Phase 3
RA Work Instability Scale -2.74 vs -0.69 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 2 more results
-2.24 vs -0.69 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-3.22 vs -0.69 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
Morning Stiffness Severity -2.84 vs -1.02 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 18 more results
-2.98 vs -1.02 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-2.83 vs -1.02 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.91 vs -1.76 placebo score @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.82 vs -1.76 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.67 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.27 vs -1.61 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.68 vs -1.76 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.83 vs -1.76 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.97 vs -1.67 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.61 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.02 vs -1.76 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.71 vs -1.76 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.07 vs -1.67 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.23 vs -1.61 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.59 vs -1.76 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.08 vs -1.76 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.5 vs -1.67 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.66 vs -1.61 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS28-CRP LDAS 22% (n=41) vs 21.1% (n=19) placebo @ 12wk60 mg
responder rate · % of participants
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more results
10.3% (n=39) vs 21.1% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
41.9% (n=62) vs 21.1% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6% (n=41) vs 21.1% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI Clinical Remission 0% (n=41) vs 0% (n=19) placebo @ 2wk60 mg
responder rate · % of participants
NCT03682705 · Phase 2 · registry result, not featured evidence
show 20 more results
2.4% (n=41) vs 0% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.3% (n=41) vs 0% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.3% (n=41) vs 5.3% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.1% (n=49) vs 4.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 0% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1% (n=39) vs 5.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 4.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.2% (n=62) vs 0% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
6.5% (n=62) vs 0% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
12.9% (n=62) vs 0% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.5% (n=62) vs 5.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
6% (n=50) vs 4.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 4.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.4% (n=41) vs 0% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 5.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=49) vs 4.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
Tender Joint Count -3.65 vs -2.47 placebo count @ 2wk60 mg
absolute change · count
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-5.16 vs -9.21 placebo count @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.43 vs -8.82 placebo count @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.14 vs -8.47 placebo count @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-3.86 vs -2.47 placebo count @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-5.39 vs -9.21 placebo count @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.83 vs -8.82 placebo count @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.33 vs -8.47 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.42 vs -2.47 placebo count @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-11.86 vs -9.21 placebo count @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-15.44 vs -8.82 placebo count @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.33 vs -8.47 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-4.88 vs -2.47 placebo count @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.08 vs -9.21 placebo count @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.08 vs -8.82 placebo count @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-12.58 vs -8.47 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -3.61 vs -3.12 placebo count @ 2wk60 mg
absolute change · count
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-5.11 vs -4.7 placebo count @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.15 vs -4.32 placebo count @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.68 vs -5.58 placebo count @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-3.3 vs -3.12 placebo count @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-4.67 vs -4.7 placebo count @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.08 vs -4.32 placebo count @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-7.85 vs -5.58 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.06 vs -3.12 placebo count @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-7.96 vs -4.7 placebo count @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-10.28 vs -4.32 placebo count @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-10.86 vs -5.58 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-4.13 vs -3.12 placebo count @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.05 vs -4.7 placebo count @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-7.58 vs -4.32 placebo count @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.59 vs -5.58 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Patient Assessment of Arthritis Pain -10.22 vs -14.97 placebo score @ 2wk60 mg
absolute change · score
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-12.95 vs -20.87 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-20.92 vs -16.21 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-19.52 vs -23.37 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.78 vs -14.97 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.41 vs -20.87 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-11.12 vs -16.21 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.46 vs -23.37 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-24.02 vs -14.97 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-28.17 vs -20.87 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-31.86 vs -16.21 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-32.27 vs -23.37 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-7.61 vs -14.97 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.91 vs -20.87 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-13.9 vs -16.21 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-17.84 vs -23.37 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · upadacitinib's landscape